Abigail Hackam

Title: Innovations in Huntington's Disease Research by Abigail Hackam

Introduction

Abigail Hackam is a prominent inventor based in Vancouver, Canada. She has made significant contributions to the field of biomedical research, particularly in understanding Huntington's disease. Her innovative work focuses on the interaction between specific proteins and the Huntington's disease gene, which has implications for potential therapies.

Latest Patents

Abigail Hackam holds a patent for "Apoptosis modulators that interact with the Huntington's disease gene." This patent describes a family of proteins, including a specific human protein designated as HIP1, which interacts differently with the gene product of a normal and an expanded Huntington's disease gene. The research indicates that the expression of the HIP1 protein is enriched in the brain and suggests a potential apoptotic function. This understanding opens up several therapeutic possibilities for Huntington's disease.

Career Highlights

Abigail Hackam is affiliated with the University of British Columbia, where she conducts her research. Her work has been instrumental in advancing the understanding of the pathology of Huntington's disease. The insights gained from her research may lead to innovative therapeutic strategies, including gene therapy and the development of peptides that can modulate apoptosis.

Collaborations

Abigail Hackam has collaborated with notable researchers in her field, including Michael Kalchman and Michael R Hayden. These collaborations have further enriched her research and contributed to the advancement of knowledge in Huntington's disease.

Conclusion

Abigail Hackam's innovative research and patent contributions are paving the way for new therapeutic approaches to Huntington's disease. Her work exemplifies the critical role of inventors in advancing medical science and improving patient outcomes.